Associated tags: BCG, Health, Professional Services, Finance, General partnership, Boston Consulting Group, Entrepreneurship, Software, Health Technology
Locations: UNITED STATES, NORTH AMERICA, NEW YORK, US, ASIA, NEW YORK CITY, LOS ANGELES, ILLINOIS, CHICAGO, EUROPE
Investment,
Learning,
Probability,
AI,
Machine learning,
Health care,
Artificial intelligence,
Growth,
Intelligence,
Venture round,
General partnership,
CDI,
Opacity MILWAUKEE, May 9, 2024 /PRNewswire/ -- Sift Healthcare ("Sift" or the "Company"), a leading innovator in AI-powered healthcare payment solutions, today announced the successful close of its $20M Series B funding round. Led by B Capital, with continued support from existing investors, including Allos Ventures, First Trust Capital Partners and Rock River Capital, Sift will use this funding to prioritize team expansion and technology investments in artificial intelligence as the Company grows its industry-first Payments Intelligence Platform.
Key Points:
- MILWAUKEE, May 9, 2024 /PRNewswire/ -- Sift Healthcare ("Sift" or the "Company"), a leading innovator in AI-powered healthcare payment solutions, today announced the successful close of its $20M Series B funding round.
- Sift's $20M Series B underscores the growing confidence in AI-powered solutions to improve the healthcare revenue cycle.
- Sift's AI-powered solutions enable healthcare organizations to leverage data to work smarter, enhance margins and accelerate cash flow.
- The Series B funding round follows the launch of Sift's Payments Intelligence Co-Pilot, RevProtect.
Technology,
Finance,
Other Construction & Property,
Commercial Building & Real Estate,
Asset Management,
Professional Services,
Construction & Property,
Artificial Intelligence,
Environment,
Sustainability,
Software,
Fintech,
Green Technology,
Climate Change,
Property management,
Real estate,
SGX,
Climate change mitigation,
Accel,
Climate,
Security (finance),
SAAS,
Carbon,
Greenhouse gas,
Singapore Exchange,
GHG,
LP record,
Infrastructure Accacia, a decarbonisation platform focusing on the Real Estate and Infrastructure sectors, has closed a US$6.5m pre-Series A round led by Illuminate Financial - a specialist VC firm focused on enterprise fintech companies building solutions for the financial services industry with offices in New York, London and Singapore.
Key Points:
- Accacia, a decarbonisation platform focusing on the Real Estate and Infrastructure sectors, has closed a US$6.5m pre-Series A round led by Illuminate Financial - a specialist VC firm focused on enterprise fintech companies building solutions for the financial services industry with offices in New York, London and Singapore.
- Real estate and construction activity contribute to about 40 percent of global Greenhouse Gas (GHG) emissions.
- With Annu’s background and industry experience in real estate, we felt Accacia is the right fit to take on a leading position in the global real estate decarbonization market and are pleased to partner with the Accacia team,” said Rezso Szabo, Partner at Illuminate Financial.
- Decarbonisation of real estate is one the biggest opportunities today – a staggering US$18 trillion of investment is required over the next decade to get the real estate industry to net zero.
Asset Management,
Professional Services,
Finance,
BCG,
Boston Consulting Group,
Climate change,
Partnership,
General partnership,
Climate,
Capital,
Carbon,
Senior advisor,
API,
Sustainability,
Renewable energy B Capital, a global multi-stage investment firm, today announced two appointments to further expand its climate investment platform.
Key Points:
- B Capital, a global multi-stage investment firm, today announced two appointments to further expand its climate investment platform.
- Additionally, Jeff Johnson has joined as General Partner to lead the firm’s growing climate investment team with nearly 25 years of experience in sustainable technology.
- Eduardo Saverin, Co-founder and Co-CEO of B Capital, added, “As more businesses integrate climate into their strategies, Rich’s strategic direction and Jeff’s investment leadership will help us partner with and back the industry’s leading climate entrepreneurs.
- “With its comprehensive global platform, unique corporate network and value-add approach, B Capital is positioned as the partner of choice for climate entrepreneurs.
Health,
Medical Devices,
Technology,
Surgery,
Health Technology,
Software,
Artificial Intelligence,
Spine,
General partnership,
FDA,
Health care,
Medtech,
U.S. Venture Partners,
Medical device Carlsmed, an AI-enabled personalized surgery Medtech company, announced today a $52.5M Series C funding round co-led by B Capital and U.S. Venture Partners.
Key Points:
- Carlsmed, an AI-enabled personalized surgery Medtech company, announced today a $52.5M Series C funding round co-led by B Capital and U.S. Venture Partners.
- These proceeds will be used to accelerate the commercialization of the aprevo® personalized spine surgery platform for lumbar fusion procedures and the development of aprevo® for cervical fusions, which will launch in 2025.
- “We started Carlsmed to improve patient outcomes through personalized surgery, and recent clinical publications indicate that aprevo® patient specific implants are achieving this goal,” stated Mike Cordonnier, CEO of Carlsmed.
- The Carlsmed implantable devices and software platforms are FDA cleared for lumbar spine fusion, including anterior, lateral, and transforaminal approaches.
Asset Management,
Professional Services,
Finance,
BCG,
Boston Consulting Group,
Growth,
Environment,
Partnership,
General partnership,
Boston,
Fund B Capital, a global multi-stage investment firm, today announced the close of B Capital Opportunities Fund II, L.P. (“Opportunities Fund II” or the “Fund”) with aggregate capital commitments of $750 million, nearly doubling the size of its predecessor B Capital Opportunities Fund I.
Key Points:
- B Capital, a global multi-stage investment firm, today announced the close of B Capital Opportunities Fund II, L.P. (“Opportunities Fund II” or the “Fund”) with aggregate capital commitments of $750 million, nearly doubling the size of its predecessor B Capital Opportunities Fund I.
- Opportunities Fund II will make primary and secondary investments in later-stage companies across B Capital’s core sectors of technology, healthcare and climate tech, with a focus on North America and Asia.
- The majority of the Fund will seek to identify follow-on investment opportunities in existing, high-performing B Capital portfolio companies.
- We are grateful for our investors, who enable us to continue to support our companies during a time when capital remains scarce,” said Raj Ganguly, Co-founder and Co-CEO at B Capital.
Neurology,
Biotechnology,
Nanotechnology,
Surgery,
Health,
Medical Devices,
Health Technology,
Technology,
Pura,
Medicine,
Neuropathic pain,
PNS,
General partnership,
Physician,
Novo,
Spinal cord stimulator,
Standard of care,
Health care,
Chronic pain,
Patient,
SCS Nalu Medical, Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-pharmacologic solutions for chronic neuropathic pain, announced today the closing of an incremental $20M in equity financing from new investor B Capital, bringing the total Series E round of equity investment to $85M.
Key Points:
- Nalu Medical, Inc. (Nalu), a private company focused on innovative, minimally invasive, and non-pharmacologic solutions for chronic neuropathic pain, announced today the closing of an incremental $20M in equity financing from new investor B Capital, bringing the total Series E round of equity investment to $85M.
- Series E was led by Novo Holdings (Novo) with $65M of the total closing in late-December 2023.
- Also participating in the round were all existing significant investors: Gilde Healthcare, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, and Aperture Venture Partners.
- “The Nalu Team is committed to addressing the unmet needs of patients suffering from chronic intractable neuropathic pain.
Professional Services,
Health,
Environment,
Health Technology,
Health Insurance,
Finance,
Banking,
Partnership,
Lightspeed Venture Partners,
Don Woods (programmer),
Business,
General partnership,
Carbon,
Stanford Graduate School of Business,
DFJ,
BCG,
Entrepreneurship,
Climate change,
Investment,
API,
Renewable energy B Capital, a global multi-stage investment firm, has announced the appointment of Don Wood as a Venture Partner focused on climate tech.
Key Points:
- B Capital, a global multi-stage investment firm, has announced the appointment of Don Wood as a Venture Partner focused on climate tech.
- In this role, Mr. Wood will expand the firm’s climate investment strategy, serve as a trusted advisor to B Capital’s growing climate team and mentor select portfolio companies.
- "The world is facing urgent challenges due to climate change, and we at B Capital are committed to investing in innovative companies that will provide returns to our investors while having a real impact,” said Sheila Patel, Vice Chair and General Partner, B Capital.
- “With Don joining our team, we are thrilled to have a seasoned climate advisor on board who can help us identify and support the most promising climate tech startups out there.”
Mr. Wood brings over 25 years of experience as a venture capitalist and climate tech specialist to his new role.
Finance,
Health,
Professional Services,
Health Technology,
Health Insurance,
General partnership,
Association of British HealthTech Industries,
Biology,
Boston Consulting Group,
AI,
MD,
Automation,
Partnership,
Health care,
Capital,
BCG,
Therapy,
Business Growth Fund,
Growth,
Capitation (healthcare),
Pharmaceutical industry B Capital, a global multi-stage investment firm, has closed the inaugural B Capital Healthcare Fund I, which, in conjunction with B Capital Growth Fund III, allocates over $500 million to opportunities across the healthcare sector, from digital health to biotech.
Key Points:
- B Capital, a global multi-stage investment firm, has closed the inaugural B Capital Healthcare Fund I, which, in conjunction with B Capital Growth Fund III, allocates over $500 million to opportunities across the healthcare sector, from digital health to biotech.
- "We are witnessing unprecedented innovation across the healthcare landscape,” said Robert Mittendorff, MD, General Partner and Head of Healthcare at B Capital.
- This moment presents a unique opportunity for B Capital to leverage our dedicated healthcare capital and active investment strategy to find and support companies advancing the healthcare sector.”
Dr. Mittendorff joined B Capital in April 2021 to lead Healthcare Fund I and B Capital’s broader healthcare initiatives globally.
- The B Capital Healthcare team is focused on deploying capital to category-defining companies that are building breakthrough products and solutions shaping the future of healthcare.
Retrieved on:
Thursday, January 19, 2023
Technology,
Finance,
Fintech,
Other Technology,
Business,
Professional Services,
Other Health,
Health,
General Health,
Boston Consulting Group,
Partnership,
Partner (business rank),
Business Growth Fund,
BCG,
Growth,
Entrepreneurship,
Financial services B Capital, a global multi-stage investment firm, today announced the close of its third venture growth fund and related companion funds (together, “Growth Fund III”), with aggregate capital commitments of approximately $2.1 billion.
Key Points:
- B Capital, a global multi-stage investment firm, today announced the close of its third venture growth fund and related companion funds (together, “Growth Fund III”), with aggregate capital commitments of approximately $2.1 billion.
- Together, these funds position B Capital to leverage the firm’s growth investing capabilities across the globe, with an emphasis on the U.S. and Asia.
- “Since its inception, B Capital has been committed to investing in cutting-edge technology companies,” said Eduardo Saverin, Co-Founder, Managing Partner at B Capital.
- “This approach drives a high-performance investment model, which we will continue to apply to the Growth Fund III series.”
The Growth III Fund series close is the latest milestone for B Capital, which most recently announced the close of its Ascent Fund II, the firm’s first dedicated early-stage fund.
Retrieved on:
Tuesday, January 10, 2023
Technology,
Finance,
Consulting,
Genetics,
Other Technology,
Health Technology,
Professional Services,
Software,
Health,
Disease,
Genetic testing,
Adoption of electronic medical records in U.S. hospitals,
Public health,
Y Combinator,
American College,
General partnership,
Nucleic acid sequence,
Polygene,
Pediatrics,
Scores,
Genomics,
American College of Medical Genetics and Genomics,
Pharmacogenomics,
Health,
Cancer,
Electronic health record,
Genetic counseling,
EMR,
Patient,
Medicine,
Medical genetics,
Pharmaceutical industry,
Nest,
Invitae Nest is an end-to-end solution designed to help health systems, clinics, pharmaceutical companies, and payors launch and scale longitudinal genomic programs.
Key Points:
- Nest is an end-to-end solution designed to help health systems, clinics, pharmaceutical companies, and payors launch and scale longitudinal genomic programs.
- The Electronic Medical Records (EMR)-integrated platform allows for the seamless incorporation of genomics into clinical practice within existing workflows, including clinical decision support to help providers create patient care plans based on the latest clinical guidelines and patient information.
- The solution also includes patient engagement tools that empower patients to understand and manage their genetic information over time.
- To realize this potential, we must address the major challenges of incorporating genetic information into provider workflows and patient care,” said Moran Snir, Nest Genomics Co-Founder and CEO.
